Real-world effectiveness and serotonin reduction in patients with progressive neuroendocrine tumors and carcinoid syndrome receiving telotristat ethyl

#3262

Introduction: Clinical trials have demonstrated the efficacy and safety of telotristat ethyl (TE) treatment in combination with somatostatin analogues (SSAs) in patients with neuroendocrine tumors (NETs) and inadequately controlled carcinoid syndrome (CS) diarrhea. The TELEACE study was designed to evaluate the real-world effectiveness of TE in US clinical practice.

Aim(s): We report clinical outcomes and biomarker changes following TE treatment in patients with worsening NET status.

Materials and methods: The design and methods of the TELEACE study have been reported previously. We analysed a subgroup of patients with worsening tumor status at the time of TE initiation based on medical chart reviews and radiological reports. Baseline CS symptoms, clinical biomarkers, Eastern Cooperative Oncology Group (ECOG) performance status, and weight were compared after at least 6 months of TE treatment.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Liu E

Authors: Liu E, Giacalone S, Joish V, Dharba S, Yarkoni T,

Keywords: neuroendocrine tumor, carcinoid syndrome, telotristat ethyl, serotonin,